Back

Tafolecimab, a novel potential long-acting PCSK9 monoclonal antibody: efficacy and safety in healthy and hypercholesterolemia subjects

( - )
Organised by:
Congress Presentation Part of: Abstract Programme Cardiovascular Pharmacotherapy ESC Premium Access ESC Asia with APSC & AFC 2020

About the speaker

Photo
Professor Yong Huo

Peking University First Hospital, Beijing (China)

238 More presentations in this session

Presentation thumbnail
2-year real-world outcomes of prasugrel, ticagrelor or clopidogrel therapy following percutaneous coronary intervention from a large multi-centre Australian registry.
Doctor D. Pol (Melbourne, AU)
Abstract
Presentation thumbnail
3D right ventricular ejection fraction and longitudinal strain are independent predictors of major adverse cardiovascular events in patients with rrhythmogenic right ventricular cardiomyopathy
Assistant Professor L. Hosseini (Bojnurd, IR)
Abstract
Presentation thumbnail
A novel pressure-regulated deployment strategy for improving the safety and efficacy of balloon-expandable transcatheter aortic valves
Doctor A. Snir (Oxford, GB)
Abstract Video
Presentation thumbnail
A novel therapeutic approach for coronary inflammation and lymphatic vessels using non-invasive low-intensity pulsed ultrasound in a porcine model with DES-induced coronary hyperconstricting responses
Doctor T. Watanabe (Sendai, JP)
Abstract Video
Presentation thumbnail
A real-world comparison of outcomes between fractional flow reserve-guided versus angiography-guided percutaneous coronary intervention
Doctor C. Wong (Sydney, AU)
Abstract

Access the full session

Session thumbnail
Abstract Programme

The Event

Event poster

ESC Asia with APSC & AFC 2020

You may be interested in
thumbnail
Congress Presentation
Time course of LDL-C lowering after initiation of PCSK9 inhibition or bempedoic acid in atherosclerotic cardiovascular disease
20 March 2026
thumbnail
Congress Presentation
Efficacy and safety of recaticimab in lowering atherogenic lipids in patients with and without coronary artery disease: a patient-level pooled analysis
28 August 2026
thumbnail
Congress Presentation
VICTORION-Mono China: efficacy and safety of inclisiran as monotherapy in Chinese adults with low or moderate ASCVD risk and elevated LDL-C
29 August 2025
thumbnail
Congress Presentation
3 September 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources